SCHEMBL2387706

SCHEMBL2387706

CNC(=O)C(OC)(OC)c1ccc(N2CCOCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.49
LMNA P02545 4/20 0.49
NPC1 O15118 2/20 0.45
PKM P14618 2/20 0.45
RAB9A P51151 2/20 0.45
ATM Q13315 1/20 0.45
TP53 P04637 1/20 0.45
MAPK1 P28482 1/20 0.45
AKR1C3 P42330 2/20 0.44
ALDH1A1 P00352 6/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 1/20 0.43
HTT P42858 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
POLB P06746 1/20 0.42
EPHX1 P07099 1/20 0.42
DGAT1 O75907 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2445203 0.89 MAPT (0.49) MAPTLMNANPC1PKMRAB9A
SCHEMBL27903899 0.87 MAPT (0.48) MAPTLMNANPC1PKMRAB9A
SCHEMBL27887007 0.82 MAPT (0.49) MAPTLMNANPC1RAB9AALDH1A1
SCHEMBL27903900 0.82 KMT2A (0.55) MAPTLMNANPC1RAB9ATP53
SCHEMBL27887165 0.77 AKR1C3 (0.47) MAPTLMNATP53AKR1C3ALDH1A1
SCHEMBL10153966 0.74 MAPT (0.64) MAPTLMNANPC1PKMRAB9A
SCHEMBL1063179 0.71 ALDH1A1 (0.67) MAPTLMNANPC1PKMRAB9A
SCHEMBL10473981 0.70 MAPT (0.56) MAPTLMNANPC1PKMRAB9A
SCHEMBL12331274 0.69 ALDH1A1 (0.51) MAPTLMNANPC1PKMRAB9A
SCHEMBL26357634 0.69 MAPT (0.51) MAPTLMNANPC1PKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2544679-B1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORP (US) 2019-05-15 EP disclosed
CN-104710385-B PDE10 inhibitor and compositions related and method 奥默罗斯公司 2018-11-09 CN disclosed
US-10106516-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2018-10-23 US disclosed
CN-107445919-A PDE10 inhibitor and compositions related and method 奥默罗斯公司 2017-12-08 CN disclosed
US-20170152238-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION 2017-06-01 US disclosed
US-9102643-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2015-08-11 US disclosed
CN-102869355-B Pde10 inhibitors and related compositions and methods OMEROS CORP 2015-07-08 CN disclosed
CN-104710385-A PDE10 inhibitors and related compositions and methods OMEROS CORP 2015-06-17 CN disclosed
US-20150133675-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION 2015-05-14 US disclosed
US-20140228581-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2014-08-14 US disclosed
CN-102869355-A Pde10 inhibitors and related compositions and methods OMEROS CORP 2013-01-09 CN disclosed
US-8343970-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2013-01-01 US disclosed
US-20110224202-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10106516-B2 PDE10 inhibitors and related compositions and methods PDE10A, PDE9A, PDE7A MAPT 229/4885LMNA 3928/4885NPC1 2865/4885
US-20140228581-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A MAPT 229/4885LMNA 3928/4885NPC1 2865/4885
US-20170152238-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A MAPT 229/4885LMNA 3928/4885NPC1 2865/4885
US-20150133675-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A MAPT 229/4885LMNA 3928/4885NPC1 2865/4885
US-20110224202-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A MAPT 229/4885LMNA 3928/4885NPC1 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.